-
公开(公告)号：US20220022851A1
公开(公告)日：2022-01-27
申请号：US17500346
申请日：2021-10-13
发明人： Masato KUSUNOKI , Yuji TOIYAMA , Koji TANAKA , Toshimitsu ARAKI , Akira MITSUI , Kenji TAKEHANA , Tsutomu UMEZAWA
摘要： The present invention provides a method for determining the likelihood of colorectal cancer development in a human ulcerative colitis patient, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions in DNA recovered from a biological sample collected from the human ulcerative colitis patient; and a determination step of determining the likelihood of colorectal cancer development in the human ulcerative colitis patient based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured in the measurement step and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a cancerous ulcerative colitis patient and a non-cancerous ulcerative colitis patient, which is set for the methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.
-
公开(公告)号：US20210206773A1
公开(公告)日：2021-07-08
申请号：US17212707
申请日：2021-03-25
申请人： EA PHARMA CO., LTD.
发明人： Tohru MIZUSHIMA , Hiroshi IWATA
IPC分类号： C07D487/04 , A61K31/5517 , A61P27/02 , A61K31/551
摘要： A new agent for the treatment of a corneal epithelium disorder, which acts directly on corneal epithelial cells, is provided. Disclosed is an agent for the treatment of a corneal epithelium disorder, the agent comprising a compound of Formula (1) or a salt thereof as an active ingredient: wherein A is an aromatic ring, a heterocyclic ring, or an aliphatic ring; R2, R3, and R4, which may be identical or different, each independently are, for example, a hydrogen atom, a halogen atom; B is an aromatic ring which may have a substituent, a heterocyclic ring which may have a substituent, or an aliphatic ring which may have a substituent; —X—, —Y—, and —Z—, which may be identical or different, each independently are O—, —NH—, —NR5—, —S—, —SO—, —SO2—, —CH2—, —CR6R7—, or —CO—; and —W— is —NR1—, —O—, or —CR8R9—.
-
公开(公告)号：US10226400B2
公开(公告)日：2019-03-12
申请号：US13892783
申请日：2013-05-13
申请人： EA Pharma Co., Ltd.
发明人： Katsumi Kouno , Hidetoshi Sakai , Kaoru Shimizu , Takahide Kawai
摘要： A multi-cell container includes a bag of substantially flat shape made of flexible film, a partition wall as a separable seal welding opposite inner surfaces of the bag and dividing an inner space of the bag into a plurality of compartments and an inlet-outlet port located at a periphery of the bag so as to be opened to one of the plurality of compartments for introduction and/or discharge of liquid. The partition wall has a horizontal section extending in a direction along the bottom of the bag and a vertical section bent therefrom and extending to the topside of the bag. A first larger volume compartment is formed on one side of the partition wall adjacent the bag bottom and a second smaller volume compartment is formed on the other side of the partition wall. The inlet-outlet port is opened to the first chamber.
-
公开(公告)号：US20190023699A1
公开(公告)日：2019-01-24
申请号：US16054077
申请日：2018-08-03
申请人： EA Pharma Co., Ltd.
发明人： Kaori KOBAYASHI , Tamotsu SUZUKI , Tatsuya OKUZUMI
IPC分类号： C07D405/14 , A61P25/00
摘要： Compounds of represented by formula (I): wherein each symbol is defined herein and pharmaceutically acceptable salts thereof exhibit TRPA1 antagonist activity and are useful as TRPA1 antagonists and the prophylaxis or treatment of diseases involving TRPA1.
-
公开(公告)号：US09533985B2
公开(公告)日：2017-01-03
申请号：US14397078
申请日：2013-04-24
申请人： EA Pharma Co., Ltd.
发明人： Hirokazu Ueno , Takashi Yamamoto , Ryuta Takashita , Ryohei Yokoyama , Toshihiko Sugiura , Shunsuke Kageyama , Ayatoshi Ando , Hiroyuki Eda , Agung Eviryanti , Tomoko Miyazawa , Aya Kirihara , Itsuya Tanabe , Tarou Nakamura , Misato Noguchi , Manami Shuto , Masayuki Sugiki , Mizuki Dohi
IPC分类号： C07D471/04 , C07D403/12 , C07D401/14 , C07D405/12 , C07D239/54 , C07D473/04 , C07D401/12 , C07D239/36 , A61P29/00
CPC分类号： C07D471/04 , C07D239/36 , C07D239/54 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D473/04
摘要： Sulfonamide compounds of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action. The compounds have formulae represented by:
摘要翻译： 提供具有特定化学结构的磺酰胺衍生物，其中作为取代基的具有杂原子作为构成元素的苯基或杂环基的磺酰胺基存在于其末端，并且其药学上可接受的 的盐。 这些化合物是具有优异的±4整联蛋白抑制作用的新化合物。
-
公开(公告)号：US20160324813A1
公开(公告)日：2016-11-10
申请号：US15216225
申请日：2016-07-21
发明人： Akihiko SAITO , Nobumasa AOKI , Yoshihisa HORI , Shoji KUWAHARA , Michihiro HOSOJIMA , Hiroshi IWATA , Saori MATSUDA
IPC分类号： A61K31/198 , B65D81/32 , A61K31/436 , A61K38/14 , A61K38/12 , A61K33/24
摘要： The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof
摘要翻译： 本发明包括西司他丁或其药学上可接受的盐作为活性成分，以及通过至少一种巨蛋白配体通过巨蛋白诱导的肾损伤或内耳障碍的抑制剂，所述巨蛋白配体选自多粘菌素，氨基糖苷类抗生素，糖肽抗生素 ，顺铂及其药学上可接受的盐
-
公开(公告)号：US20190352721A1
公开(公告)日：2019-11-21
申请号：US16333130
申请日：2017-09-28
发明人： Masato KUSUNOKI , Yuji TOIYAMA , Akira MITSUI , Kenji TAKEHANA , Tsutomu UMEZAWA
IPC分类号： C12Q1/6886 , A61B10/02 , G16H50/30 , G16B40/10
摘要： The present invention provides a method for determining the likelihood of sporadic colorectal cancer development, the method including: a measurement step of measuring methylation rates of one or more CpG sites present in specific differentially methylated regions, in DNA recovered from a biological sample collected from a human subject; and a determination step of determining the likelihood of sporadic colorectal cancer development in the human subject, based on average methylation rates of the differentially methylated regions which are calculated based on the methylation rates measured and a preset reference value or a preset multivariate discrimination expression, in which the reference value is a value for identifying a sporadic colorectal cancer patient and a non-sporadic colorectal cancer patient, which is set for the average methylation rate of each differentially methylated region, and the multivariate discrimination expression includes, as variables, average methylation rates of one or more differentially methylated regions among the specific differentially methylated regions.
-
公开(公告)号：US10166234B2
公开(公告)日：2019-01-01
申请号：US15992321
申请日：2018-05-30
申请人： EA Pharma Co., Ltd.
IPC分类号： A61K31/517 , A61P1/00 , A61P29/00 , A61K9/20 , A61K9/28
摘要： The disclosed pharmaceutical preparation comprises a compound represented by the chemical formula (A) or a pharmaceutically acceptable salt thereof, which is dispersed in a matrix consisting of a water-soluble high molecular weight substance; and Crospovidone: The pharmaceutical preparation is excellent in the solubility and the storage stability even if the amount of the compound or the salt included in each individual dosage unit is increased.
-
9.发明申请公开(公告)号：US20180230122A1
公开(公告)日：2018-08-16
申请号：US15953787
申请日：2018-04-16
申请人： EA PHARMA CO., LTD.
IPC分类号： C07D333/40
CPC分类号： C07D333/40
摘要： Compounds of formula (VI), which are useful as therapeutic drugs for diabetes, may be produced by reacting a compound of formula (II) with an acid halogenating agent to give an acid halide; reacting the acid halide with a compound of formula (IV) in the presence of a base, and crystallizing compound (V) or a salt thereof from the reaction system; and subjecting the compound of formula (V) to reductive deprotection in the presence of a metal catalyst, and crystallizing the compound of (VI) or a salt thereof from the reaction system:
-
公开(公告)号：US09883986B2
公开(公告)日：2018-02-06
申请号：US14155420
申请日：2014-01-15
申请人： EA Pharma Co., Ltd.
发明人： Shota Mochizuki , Naoki Morinaka
CPC分类号： A61J1/10 , A61J1/1462 , A61J1/1493 , A61J2200/76 , A61M1/1601 , A61M2025/0059 , A61M2205/3334 , B65B3/003 , B65B55/022 , F04C2270/0421
摘要： The present invention relates to a standing bag type container and aims to increase a visibility of the residual liquid volume in accordance with the progress of infusion process. The standing bag type container includes a bag 10 made of soft resin films and forming at its one end a base member 20 and an outlet port 18 at the other end of the bag. A suspension of the bag 10 is done in a manner that the base member 20 is located at the top. Marks for indication of residual liquid volume are printed on the surface of the bag. An infusion liquid is charged to the bag while an air gap 109′ is left, so that a residual liquid volume is verified from the liquid level. Under the suspended condition, the base member 20 has a value of width which is unchanged from the when the bag is under upright condition. The base member 20 is not collapsed and maintains its width even when the residual liquid volume is zero. A portion of the bag of a predetermined height from the top edge of the bag including the base member 20 maintains its shape without being collapsed by a discharge of the liquid.
-
-
-
-
-
-
-
-
-
搜索结果
39 条记录 (耗时 0.029 秒)
